A major advance in cancer study is arising with the use of VHH fragments to re-engage dysfunctional p53. This vital cancer inhibitor protein is frequently inactivated in many types of cancer, resulting uncontrolled https://express-page.com/story7443595/mini-antibodies-reactivate-tumor-suppressor-p53-the-new-pathway-for-tumor-management